Skip to main
PEPG
PEPG logo

PepGen Inc (PEPG) Stock Forecast & Price Target

PepGen Inc (PEPG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 0%
Sell 20%
Strong Sell 0%

Bulls say

PepGen Inc. demonstrates a positive outlook due to the encouraging preliminary results from the FREEDOM-DM1 trial, which showcased a dose-dependent increase in splicing correction and a significant four-fold enhancement in oligonucleotide enrichment in muscle tissue. The company's Enhanced Delivery Oligonucleotide (EDO) platform has shown robust efficacy while maintaining strong safety profiles, with the current data indicating potential therapeutic benefits in the DM1 landscape, especially as they plan to escalate dosing to 20 mg/kg. Furthermore, the reliable efficacy metrics, including a 29.1% splicing correction surpassing the crucial therapeutic threshold, support a favorable long-term view on the company’s ability to innovate within the neuromuscular disease treatment space.

Bears say

PepGen Inc reported a net loss of $22 million, translating to a loss of $0.68 per share in the fourth quarter, indicating significant financial strain on the company. The probability of success for its lead product, PGN-EDO51, has been lowered from 40% to 25% due to safety concerns, particularly related to kidney function as evidenced by decreased estimated glomerular filtration rate (eGFR) among study participants. Furthermore, multiple risks threaten the future of PGN-EDO51, including potential failures in clinical studies, regulatory approvals in key markets (US and EU), and challenges in achieving projected peak commercial revenues.

PepGen Inc (PEPG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PepGen Inc (PEPG) Forecast

Analysts have given PepGen Inc (PEPG) a Buy based on their latest research and market trends.

According to 5 analysts, PepGen Inc (PEPG) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PepGen Inc (PEPG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.